Logo 1.png
Aeterna Zentaris Announces Final Settlement of Previously Disclosed Class-Action Lawsuit
June 03, 2021 08:05 ET | Aeterna Zentaris Inc
CHARLESTON, S.C., June 03, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and...
Logo 1.png
Aeterna Zentaris to Present at the Q2 Virtual Investor Summit
May 10, 2021 08:05 ET | Aeterna Zentaris Inc
– Live video webcast with CEO, Dr. Klaus Paulini, on Monday, May 17, 2021 at 8:45 AM ET CHARLESTON, S.C., May 10, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the...
Logo 1.png
Aeterna Zentaris Announces Results of 2021 Annual Meeting of Shareholders
May 05, 2021 16:35 ET | Aeterna Zentaris Inc
CHARLESTON, S.C., May 05, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing...
PAVMEDLOGONEW15OCT2018.png
PAVmed Partners with Laser Technology Pioneer Dr. Jacob Wong to Develop and Commercialize Non-Invasive Laser-based Diagnostic Products
November 14, 2019 09:30 ET | PAVmed Inc.
Secures exclusive worldwide license for Nondispersive Infrared (NDIR) laser technology Launches joint development program for NDIR laser-based diagnostic products to measure glucose, electrolytes...
Logo.png
Interpace Enters Strategic Partnership Agreement with Genecast Biotechnology to Partner with Biopharma Solutions in China
September 16, 2019 06:55 ET | Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc.’s subsidiary, Interpace BioPharma Inc. (“Interpace”, “Interpace BioPharma” or the “Company”) today announced that...
Zyomyx Logo
Zyomyx Receives $7.5 Million From UNITAID to Launch Rapid, Service-Free Point-of-Care CD4 Test
March 26, 2014 07:30 ET | Zyomyx
FREMONT, Calif., March 26, 2014 (GLOBE NEWSWIRE) -- Zyomyx, Inc. has been awarded US$7.5 million from UNITAID to commercialize its quantitative MyT4™ point-of-care CD4 test, designed to guide...
Zyomyx Logo
Zyomyx Receives CE Mark for Its New MyT4(TM) Point-of-Care CD4 Test
January 09, 2014 07:30 ET | Zyomyx
FREMONT, Calif., Jan. 9, 2014 (GLOBE NEWSWIRE) -- Zyomyx, Inc., a provider of innovative point-of-care diagnostic tests, announced today that it received the CE Mark for its MyT4™ point-of-care...